XML 52 R42.htm IDEA: XBRL DOCUMENT v3.19.1
Basis of Presentation - Adoption of New Revenue Recognition Standard Revenue Impacted Previously Reported (Detail) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Mar. 31, 2019
Mar. 31, 2018
Jun. 30, 2018
Consolidated Statements of Operations:                  
Total revenue $ 216.6     $ 183.1 [1]     $ 635.7 $ 549.8 [1]  
Selling, general, and administrative expense 140.6     107.9 [1]     405.7 322.3 [1]  
Income tax provision (3.6)     4.3 [1]     (1.0) (16.7) [1]  
Net income attributable to Myriad Genetics, Inc. stockholders $ 6.9 $ 2.6 $ (0.7) $ 9.1 [1] $ 30.9 $ 78.9 $ 8.8 $ 118.9 [1]  
Earnings per share:                  
Basic $ 0.09     $ 0.13 [1]     $ 0.12 $ 1.72 [1]  
Diluted $ 0.09     $ 0.13 [1]     $ 0.12 $ 1.66 [1]  
Consolidated Statements of Cash Flows:                  
Net income attributable to Myriad Genetics, Inc. stockholders $ 6.9 $ 2.6 $ (0.7) $ 9.1 [1] $ 30.9 $ 78.9 $ 8.8 $ 118.9 [1]  
Trade accounts receivable             (27.0) (14.4) [1]  
Consolidated Balance Sheet:                  
Trade accounts receivable 142.6           142.6   $ 99.5 [1]
Retained earnings $ 29.8           $ 29.8   54.1 [1]
ASC 606 | As Previously Reported                  
Consolidated Statements of Operations:                  
Total revenue       191.1       571.7  
Selling, general, and administrative expense       115.1       345.5  
Income tax provision       4.5       (17.0)  
Net income attributable to Myriad Genetics, Inc. stockholders       $ 9.7       $ 118.0  
Earnings per share:                  
Basic       $ 0.14       $ 1.71  
Diluted       $ 0.13       $ 1.66  
Consolidated Statements of Cash Flows:                  
Net income attributable to Myriad Genetics, Inc. stockholders       $ 9.7       $ 118.0  
Trade accounts receivable               (42.3)  
Consolidated Balance Sheet:                  
Trade accounts receivable                 98.3
Retained earnings                 52.9
ASC 606 | Adjustments                  
Consolidated Statements of Operations:                  
Total revenue       (8.0)       (21.9)  
Selling, general, and administrative expense       (7.2)       (23.2)  
Income tax provision       (0.2)       0.3  
Net income attributable to Myriad Genetics, Inc. stockholders       $ (0.6)       $ 0.9  
Earnings per share:                  
Basic       $ (0.01)       $ 0.01  
Diluted       $ (0.01)          
Consolidated Statements of Cash Flows:                  
Net income attributable to Myriad Genetics, Inc. stockholders       $ (0.6)       $ 0.9  
Trade accounts receivable               $ (27.9)  
Consolidated Balance Sheet:                  
Trade accounts receivable                 1.2
Retained earnings                 $ 1.2
[1] Amounts adjusted due to the adoption of Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606). See Note 1 to the financial statements contained in Part I, Item 1 of this report for additional information.